Phyla, based in Montreal, Canada, is a digital health company developing the first end-to-end solution for individuals with IBD and IBS. Phyla combines at-home microbiome stool testing with digital health technology to generate customized and data-driven recommendations for its users.
Phyla's technology consists of a microbiome stool test subscription and a mobile Android/IOS application through which users can track their microbiome test results, medication usage, mood, sleep, diet and other lifestyle parameters. Phyla’s platform interprets the stool testing and self-reported results using artificial intelligence algorithms and provides users with recommendations and educational materials.
Phyla is looking for partners who have access to German IBD and IBS patients. It is also seeking clinical collaborations with healthcare centres, research organizations or pharmaceutical companies in order to validate the usage of its digital health platform in a real-world setting.